In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Stents: J&J Innovates, Others Stumble

Executive Summary

In traditional coronary stents, Cordis/J&J initially dominated the market, only to dramatically lose market share because of its inability to come up with a next generation product quickly enough, before becoming competitive again. In drug-eluting stents, which look to be the next blockbuster cardiovascular product, J&J again has an early lead, but this time its competitors have stumbled.

You may also be interested in...

Business & Technology Briefs (02/2007)

A short summary of recent market and product developments covering Peripheral Interventions, Cardiovascular and Orthopedic/Spine Surgery, and Oncology.

Next Drug Stent Trials: Medtronic Goes to Europe, Guidant Stays Home

Medtronic and Guidant need to play catch-up in the stent race to see who's going to be third behind Cordis/J&J's Cypher, which is approved in the US, and Boston Scientific's Taxus, which is expected to be approved shortly. A key component of Medtronic's and Guidant's competitive strategies will be deciding whether to do trials in the US vs. doing them internationally. Medtronic is doing its pivotal study in Europe, while Guidant is doing its in the US.

Conor: An Outsider Delivers Drug-Stents' Next Generation

Drug-eluting stents (DES), now approved in the US, will be the first blockbuster combination drug/device product to hit the market. First generation DES products use a stent design that remains basically unchanged from bare metal stents, bascially adding thin layers of drug and polymer coatings. Conor Medsystems is developing a stent that is specifically designed as a drug delivery vehicle, while still embodying the attributes required of a standard stent. Conor's stent is based on work done by an engineer with no expereince in the medical products industry, based on technology developed in other areas, bringing a fresh look to the future of combining drugs and stents that may extend to therapeutic applications beyond treating only cardiovascular disease.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts